Learn more about our programs
Atopic Dermatitis

Truths & Myths About Chronic Spontaneous (Idiopathic) Urticaria (CSU or CIU): What I Need to Know to Advocate for My Care

Now Available On Demand

  Watch Now

Produced in collaboration with Asthma and Allergy Foundation of America
Support for this patient education program was provided by Genentech

Chronic Idiopathic Urticaria (CIU), also named Chronic Spontaneous Urticaria (CSU), is a dermatologic condition characterized by the presence of swelling and hives that appear unpredictably on almost any part of the body and can occur without an identifiable trigger.

During this presentation the faculty panel will share information and strategies to help patients and caregivers in their discussions with their doctors about their symptoms, their experience with the disease, and what they can do to manage it. This is part 1 of a 2 part series. Part 2 is an educational activity for clinicians, in which learning and key questions from patients will be further discussed by the expert faculty panel.

After attending this program you will be able to:

  • Recognize the nature and the timing of what the symptoms may indicate and relay the information to a doctor
  • Understand that CSU (CIU) symptoms may only affect the skin, that hives may disappear over time, and that there is usually no specific cause that can be identified and avoided
  • Differentiate myth from facts regarding the cause of CSU (CIU) and its management and locate educational resources and local support communities
  • Engage with the health care provider regarding treatment recommendations
  • Understand that lasting improvements in the skin’s appearance and swelling necessitates adherence to an effective treatment plan, keep track of progress and report any changes promptly to a health care provider

Register now to watch on demand.




Allen P. Kaplan, MD

Professor of Medicine
Medical University of South Carolina

Allen Kaplan, MD, is professor of medicine at The Medical University of South Carolina in Charleston. Dr Kaplan was head of the Allergic Diseases Section of the NIAID for 6 years, head of the Division of Allergy, Rheumatology, and Clinical Immunology, and chairman of the Department of Medicine at Stony Brook University for 19 total years. Author of over 365 publications, his interests are mechanisms for production of bradykinin and its role in human disease, and pathogenesis and treatment of urticaria and angioedema. Dr Kaplan has been president of AAAAI, the Clinical Immunology Society, and The World Allergy Organization. He edited The Journal of The World Allergy Organization for five years and has edited or co-edited many other notable journals and textbooks.

Jonathan A. Bernstein, MD

Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section
Bernstein Allergy Group and Bernstein Clinical Research Center

Jonathan A. Bernstein, MD, is professor of clinical medicine in the Department of Internal Medicine, Division of Immunology/Allergy Section at the University of Cincinnati Medical Center and partner of the Bernstein Allergy Group and Clinical Research Center in Cincinnati, Ohio. His research, which has resulted in over 310 peer reviewed articles, involves effects of environmental interventions in homes of asthmatic children, and therapies for treatment of angioedema/chronic urticaria. Dr Bernstein is vice-chairman of the AAAAI Foundation, president of Interasma, and chairman of AFI. He was the recipient of the 2019 AAAAI Distinguished Clinician and WAO Outstanding Clinician awards. Dr Bernstein has been ranked by US News and World Report as being in the top 1% of doctors in his specialty.

Sanaz Eftekhari

Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America (AAFA)

Sanaz Eftekhar, vice president of Corporate Affairs and Research at AAFA, leads tactical and strategic conversations with business partners and stakeholders across multiple industries. She has been instrumental in working with AAFA’s partners to present patient perspectives on the needs for atopic dermatitis treatments to the US Food and Drug Administration. In a greater effort to connect patients with vital clinical trials, Sanaz has been a key player in the development of AAFA’s upcoming clinical trial database. She has led AAFA’s involvement in the CIU & You campaign since its launch in 2015, co-authored several key AAFA research reports, and serves as secretary on the Board of Directors for the Global Allergy & Airways Patient Platform (GAAPP).


Partners and Supporters

  • Asthma and Allergy Foundation of America